Consolidation Therapy After Complete Resection of High-Risk Neuroblastoma
For most patients with high-risk neuroblastoma after complete resection, proceed with tandem high-dose chemotherapy with autologous stem cell rescue (two consecutive rounds), followed by consolidative radiotherapy to the primary site at 21.6 Gy, then postconsolidation immunotherapy with anti-GD2 antibody plus isotretinoin. This represents the current standard of care based on randomized trial evidence.
Consolidation Phase Components
High-Dose Chemotherapy with Stem Cell Rescue
Tandem transplantation is the Category 1 recommendation for most high-risk patients 1. The COG ANBL0532 randomized phase 3 trial demonstrated that patients receiving tandem transplant (thiotepa/cyclophosphamide followed 6-10 weeks later by dose-reduced carboplatin/etoposide/melphalan) had significantly improved 3-year event-free survival of 61.6% versus 48.4% for single transplant 1.
Two specific subgroups may receive single transplant instead:
- Stage L2, ≥18 months at diagnosis, unfavorable histology, AND MYCN non-amplified
- Stage M, 12 to <18 months at diagnosis, MYCN non-amplified, with unfavorable histology, diploid DNA, or segmental chromosomal aberrations
These subgroups historically achieve 5-year event-free survival of 75-80%, justifying less intensive consolidation 1.
Consolidative Radiotherapy
Administer 21.6 Gy to the primary tumor site after recovery from high-dose chemotherapy 1.
Do not extend radiation fields to uninvolved draining lymph nodes - COG trial A3973 showed no benefit with similar local relapse rates 1.
Do not boost gross residual tumor beyond 21.6 Gy - COG ANBL0532 showed that adding 14.4 Gy boost to gross residual disease did not improve local control or event-free survival 1.
Radiate residual metastatic sites visible on MIBG or FDG-PET at end-induction evaluation when feasible, though this North American approach is not universally adopted internationally 1.
Postconsolidation Immunotherapy
All patients without progressive disease after consolidation should receive anti-GD2 antibody-based postconsolidation therapy (Category 1 recommendation) 1.
The ANBL0032 trial demonstrated 2-year event-free survival of 66% with dinutuximab + cytokines + isotretinoin versus 46% with isotretinoin alone 1.
Current recommended regimen:
- Dinutuximab with sargramostim (cycles 1,3,5) + isotretinoin
- Omit interleukin-2 - the SIOPEN HR-NBL1 trial showed IL-2 added no benefit and increased toxicity 1
Alternative: Dinutuximab beta with isotretinoin (without sargramostim) is standard in Europe and shows higher event-free survival versus historical isotretinoin-alone controls 1.
Continuation Therapy
Consider discussing eflornithine (Category 2B recommendation) for patients achieving partial response or better after completing anti-GD2 immunotherapy 1.
FDA-approved December 2023 based on Study 3b showing improved outcomes versus external controls (event-free survival HR 0.48, overall survival HR 0.32), though residual confounding remains possible in this non-randomized comparison 1.
Dose: 750 mg/m² ± 250 mg/m² twice daily for up to 2 years 1.
Critical monitoring: Serial audiograms or brainstem auditory evoked response testing is essential, as most high-risk neuroblastoma patients are at critical ages for language development and eflornithine causes hearing loss 1.
Important Caveats
- These recommendations apply to patients achieving partial response or better to induction therapy 1
- Patients with progressive disease during/after induction should receive non-myeloablative chemoimmunotherapy or clinical trial enrollment instead of consolidation 1
- The historical randomized trials establishing high-dose chemotherapy benefit preceded routine anti-GD2 immunotherapy use; some single-institution data suggest similar overall survival with/without high-dose chemotherapy in patients with >partial response in the immunotherapy era, though this requires further validation 1
- Busulfan/melphalan is preferred in Europe with superior event-free survival versus carboplatin/etoposide/melphalan after COJEC induction, but its role in North American treatment algorithms remains undefined 1